Laminar Pharma Concludes Patient Monitoring in Glioblastoma Trial

Laminar Pharma has reached a significant milestone by completing the final patient visit in its Phase 2b/3 clinical trial for LAM561, an experimental treatment for newly diagnosed glioblastoma. This marks the end of the active clinical monitoring phase, where the therapy was evaluated in combination with standard care. The trial's progression indicates movement towards potential future data analysis and regulatory steps.